Engineering multivalent antibody fragments for in vivo targeting.

[1]  A A Raubitschek,et al.  Multimerization of a chimeric anti-CD20 single-chain Fv-Fc fusion protein is mediated through variable domain exchange. , 2001, Protein engineering.

[2]  R. Kontermann,et al.  Optimized linker sequences for the expression of monomeric and dimeric bispecific single-chain diabodies. , 2001, Protein engineering.

[3]  S. Batra,et al.  99mTc-labeled divalent and tetravalent CC49 single-chain Fv's: novel imaging agents for rapid in vivo localization of human colon carcinoma. , 2001, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[4]  A. Plückthun,et al.  Tumor Targeting of Mono-, Di-, and Tetravalent Anti-p185HER-2 Miniantibodies Multimerized by Self-associating Peptides* , 2001, The Journal of Biological Chemistry.

[5]  Y. Lin,et al.  Preclinical evaluation of a humanized NR-LU-10 antibody-streptavidin fusion protein for pretargeted cancer therapy. , 2001, Cancer biotherapy & radiopharmaceuticals.

[6]  S. Batra,et al.  Genetically engineered tetravalent single-chain Fv of the pancarcinoma monoclonal antibody CC49: improved biodistribution and potential for therapeutic application. , 2000, Cancer research.

[7]  A. Wu,et al.  Designer genes: recombinant antibody fragments for biological imaging. , 2000, The quarterly journal of nuclear medicine : official publication of the Italian Association of Nuclear Medicine (AIMN) [and] the International Association of Radiopharmacology.

[8]  A. Kortt,et al.  ScFv multimers of the anti-neuraminidase antibody NC10: shortening of the linker in single-chain Fv fragment assembled in V(L) to V(H) orientation drives the formation of dimers, trimers, tetramers and higher molecular mass multimers. , 2000, Protein engineering.

[9]  S S Gambhir,et al.  High-resolution microPET imaging of carcinoembryonic antigen-positive xenografts by using a copper-64-labeled engineered antibody fragment. , 2000, Proceedings of the National Academy of Sciences of the United States of America.

[10]  B. Davidson,et al.  Radioimmunoguided surgery in colorectal cancer using a genetically engineered anti-CEA single-chain Fv antibody. , 2000, Clinical cancer research : an official journal of the American Association for Cancer Research.

[11]  A. Kortt,et al.  High avidity scFv multimers; diabodies and triabodies. , 1999, Journal of immunological methods.

[12]  E. Padlan,et al.  Generation and characterization of a single gene-encoded single-chain-tetravalent antitumor antibody. , 1999, Clinical cancer research : an official journal of the American Association for Cancer Research.

[13]  R. Kontermann,et al.  Novel tetravalent and bispecific IgG‐like antibody molecules combining single‐chain diabodies with the immunoglobulin γ1 Fc or CH3 region , 1999, FEBS letters.

[14]  A. Kortt,et al.  scFv multimers of the anti-neuraminidase antibody NC10: length of the linker between VH and VL domains dictates precisely the transition between diabodies and triabodies. , 1999, Protein engineering.

[15]  M. Little,et al.  Di‐, tri‐ and tetrameric single chain Fv antibody fragments against human CD19: effect of valency on cell binding , 1999, FEBS letters.

[16]  L. Zardi,et al.  Increased binding affinity and valence of recombinant antibody fragments lead to improved targeting of tumoral angiogenesis. , 1999, Cancer research.

[17]  G. Adams,et al.  Prolonged in vivo tumour retention of a human diabody targeting the extracellular domain of human HER2/neu. , 1998, British Journal of Cancer.

[18]  S. Larson,et al.  Single chain antigen binding protein (sFv CC49) , 1997, Cancer.

[19]  E. Ward,et al.  FcRn: the MHC class I-related receptor that is more than an IgG transporter. , 1997, Immunology today.

[20]  A. Murzin,et al.  The 2.0-A resolution crystal structure of a trimeric antibody fragment with noncognate VH-VL domain pairs shows a rearrangement of VH CDR3. , 1997, Proceedings of the National Academy of Sciences of the United States of America.

[21]  P. Iliades,et al.  Triabodies: single chain Fv fragments without a linker form trivalent trimers , 1997, FEBS letters.

[22]  O. Burrone,et al.  Mammalian cell expression of dimeric small immune proteins (SIP). , 1997, Protein engineering.

[23]  V. Joshi,et al.  Pharmacological actions of Pongamia pinnata seeds--a preliminary study. , 1996, Indian journal of experimental biology.

[24]  A. George,et al.  Single-chain Fv radioimmunotargeting. , 1996, The quarterly journal of nuclear medicine : official publication of the Italian Association of Nuclear Medicine (AIMN) [and] the International Association of Radiopharmacology.

[25]  R. Hawkins,et al.  Clinical evidence of efficient tumor targetting based on single–chain Fv antibody selected from a combinatorial library , 1996, Nature Medicine.

[26]  T. Logtenberg,et al.  Leucine Zipper Dimerized Bivalent and Bispecific scFv Antibodies from a Semi-synthetic Antibody Phage Display Library (*) , 1996, The Journal of Biological Chemistry.

[27]  L E Williams,et al.  Tumor localization of anti-CEA single-chain Fvs: improved targeting by non-covalent dimers. , 1996, Immunotechnology : an international journal of immunological engineering.

[28]  P. Hand,et al.  Biological properties of chimeric domain-deleted anticarcinoma immunoglobulins. , 1995, Cancer research.

[29]  A. Plückthun,et al.  Tetravalent miniantibodies with high avidity assembling in Escherichia coli. , 1995, Journal of molecular biology.

[30]  M. Little,et al.  Bifunctional and multimeric complexes of streptavidin fused to single chain antibodies (scFv). , 1995, Journal of immunological methods.

[31]  R. Williams,et al.  Crystal structure of a diabody, a bivalent antibody fragment. , 1994, Structure.

[32]  M. Little,et al.  Isolation of IgG antibody Fv-DNA from various mouse and rat hybridoma cell lines using the polymerase chain reaction with a simple set of primers. , 1994, Journal of immunological methods.

[33]  A. Lawson,et al.  Multimerization behaviour of single chain Fv variants for the tumour-binding antibody B72.3. , 1994, Protein engineering.

[34]  W. Harris,et al.  Spontaneous assembly of bivalent single chain antibody fragments in Escherichia coli. , 1994, Molecular immunology.

[35]  K. D. Hardman,et al.  An improved linker for single-chain Fv with reduced aggregation and enhanced proteolytic stability. , 1993, Protein engineering.

[36]  L L Houston,et al.  Highly specific in vivo tumor targeting by monovalent and divalent forms of 741F8 anti-c-erbB-2 single-chain Fv. , 1993, Cancer research.

[37]  T Prospero,et al.  "Diabodies": small bivalent and bispecific antibody fragments. , 1993, Proceedings of the National Academy of Sciences of the United States of America.

[38]  T. Yokota,et al.  Rapid tumor penetration of a single-chain Fv and comparison with other immunoglobulin forms. , 1992, Cancer research.

[39]  A. Plückthun,et al.  Miniantibodies: use of amphipathic helices to produce functional, flexibly linked dimeric FV fragments with high avidity in Escherichia coli. , 1992, Biochemistry.

[40]  K. D. Hardman,et al.  Single-chain antigen-binding proteins. , 1988, Science.

[41]  R. Bruccoleri,et al.  Protein engineering of antibody binding sites: recovery of specific activity in an anti-digoxin single-chain Fv analogue produced in Escherichia coli. , 1988, Proceedings of the National Academy of Sciences of the United States of America.